chemical approaches to the disruption of telomerase function chemical approaches to the disruption...
TRANSCRIPT
Chemical Approaches to theDisruption of Telomerase Function
Chemical Approaches to theDisruption of Telomerase Function
Joseph StringerBlackwell Group 1.25.07
2
Cancer
- 1,444,000 predicted new cases diagnosed in 2007 (U.S.)
- 559,650 expected deaths from cancer in 2007 (U.S)
- 2nd leading cause of death (U.S.)- $206 billion cancer costs in 2006 (U.S)
- Emotional aspect
www.cancer.org
3
Traditional Cancer TreatmentsRadiotherapy – damaging DNA by ionization
not selective/highly toxic
Surgery – removal of malignant tumordifficult to
remove/invasive
Chemotherapy – use of drugsside effects
Telomerase inhibitors – selective/minimal side effects
4
Biology Basics
Human body
Systems
Organs
Tissue Cells
Nucleus
Chromosomes
DNA
5
DNA Basics
5'
3'
3'
5'
6
End Replication Problem
3'
3'
5'
5'
5'
3'
5'
3'
replication
replication
replication
Cell death
Critically short DNA
3'5'
5'
3'
5'3'
5'
3'
7
Human Telomere
- Long telomeres have many protective proteins- Critically short telomeres have few protective
proteins- Critically short telomeres are vulnerable
www.cancer.org
8
Human Telomere
……………………TTAGGGTTAGGGTTAGGGTTAGGGTTAGGG
……………………AATCCCAATCCCAATCCC (5,000-20,000 bases) (100-400 bases)
Double-stranded Single-stranded
Rest of DNA
Telomere region
-Telomere DNA does NOT code for any genetic information
9
Cell Division
Cancer cell – “immortal”
Shay, J.W., et al. Nature Reviews Drug Discovery 2006, online.
The telomerase enzyme maintainstelomere length in cancer cells,preventing cell death
Normal cell – cell death
10
Telomerase Enzyme
Shay, J.W., et al. Nature Reviews Drug Discovery 2006, online.
Active in ~85% of cancer cells
Absent/undetectable in normal, healthy cells
Telomerase active
Telomerase NOT active
Normal cell – cell death Cancer cell – “immortal”
11
Telomerase Timeline
Telomerase discovered(Blackburn/Greider)
Telomerase activity in cancercells, but not healthy cells(Kim)
Telomere ligandInhibits telomerase(Hurley)
Telomerase doesNOT cause cancer(Wright/Shay)
Crystal structureof human telomere(Neidle)
Wright, W., Shay, J., Nature Reviews Drug Discovery 2006, online.
12
Targeting Telomerase Activity
Inhibit telomeraseassembly proteins
Inhibit telomeraseassembly proteins Telomerase enzyme
-RNAi-RT inhibitors (HIV)-Artificial peptides
Telomerase enzyme-RNAi-RT inhibitors (HIV)-Artificial peptides
RNA template-Peptide nucleic acid (PNA)-Antagonist oligonucleotides
RNA template-Peptide nucleic acid (PNA)-Antagonist oligonucleotides
Telomere-Stabilizing ligands
Telomere-Stabilizing ligands
Gellert, G.C., et al. Drug Discovery Today 2005, 2, 159-164.
13
Guanine - Quadruplex
Zahler, A.M., et al. Nature 1991, 350, 718-719.Gabelica, V., et al. J. Am. Chem. Soc. 2006, 128, 2641-2648
Highly stable G-quadruplex (G4)can inhibit telomerase activity
……TTAGGGTTAGGGTTAGGGTTAGGGTTAGGG……AATCCCAAT
14
G4 Inhibitors -Proposed Mechanism
5'
3'
+ G4 Ligand
…………TTAGGGTTAGGGTTA…………AATCCCAATCCC
…………TTAGGGTTAGGGTTAGGGTTAGGG…………AATCCCAATCCC
(TTAGGG)n
Inhibition ofelongation …cell dies
Telomere elongation… cell lives
Telomerase
15
G4 Selectivity
- Structural diversity provides basis for selective recognition between duplex DNA vs. G4 DNA
- π stacking potential on guanine faces
vs.
duplex DNA G4 DNA
Neidle, S., Read, M.A., Biopolymers 2001, 56, 195-208.Baker, E.S., et al. J. Am. Chem. Soc. 2006, 128, 2641-2648.
16
G4 Ligand Design
- DNA intercalators are toxic- Characterized by large, flat aromatic core,
possibly protonated in center- Need to design ligands selective for G4
DNA
Common DNA intercalators
Chan, A., et al. J. Med. Chem. 2005, 48, 7315-7321.
Cryptolepine Proflavine Ethidium bromide
DNA Intercalated DNA
17
Classes of G4 Ligands
Polycycles Macrocycles
18
Acridine Derivative
- Synthesized in 2001 based on parent acridine intercalator- - 45:1 selectivity for G4 DNA vs. duplex DNA- Phase I/II clinical trial (Antisoma)
Read, M., et al. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4844-4849.
EC50 115 nM
19
BRACO19 Synthesis
Read, M., et al. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4844-4849.
20
BRACO19
Read, M., et al. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4844-4849.
G4 DNA
21
Quinoline Derivatives
Guyen, B., et al. Org. Biomol. Chem. 2004, 2, 981-988.
ΔTm G4 ΔTm dsDNA
quinoline der.
13.0°C 0.0°C
BRACO19 27.5°C -
EC50 ~ 6.3µM
22
Quinoline Synthesis
Guyen, B., et al. Org. Biomol. Chem. 2004, 2, 981-988.
23
G4 Crystal Structure
Parkinson, G.N., Lee, M.P.H., Neidle, S., Nature 2002, 417, 876-880.
Axial view
Side view
=
π stackingpartial (+) charge
Interaction with (-) chargedphosphate backbone
24
“Clicked” Triazoles
- π stacking with guanine faces
Moorhouse, A.D., et al. J. Am. Chem. Soc. 2006, 128, 15972-15973.
ΔTm G4
ΔTm dsDNA
triazole 18.7°C 0.0°C
BRACO19 27.5°C -
25
“Clicked” Triazoles
- “Click chemistry”, highly flexible- Selective for G4 DNA vs. duplex DNA- Generation of π stacking motif
Moorhouse, A.D., et al. J. Am. Chem. Soc. 2006, 128, 15972-15973.
26
Classes of G4 Ligands
Polycycles Macrocycles
27
Telomestatin
- First isolated in 2001 from Streptomyces anulatus
- - Total synthesis
finished in 2006, 21 steps, <1% overall yield
- First natural product shown to bind selectively to G4 DNA
Shin-ya, K., et al. J. Am. Chem. Soc. 2001, 123, 1262-1263.Doi, T., et al. Org. Lett. 2006, 8, 4165-4167.
EC50 5 nM
28
Cyclic Oxazoles
- Minimal duplex DNA stabilization
- 8 steps, ~14% overall yield
Minhas, G.S., et al. Bioorg. Med. Chem. Lett. 2006, 16, 3891-3895.Jantos, K., et al. J. Am. Chem. Soc. 2006, 128, 13662-13663.
R stereochem.
ΔTm G4 ΔTm dsDNA
(CH2)4NH2 R,R,R 6.4°C 0.0°C
telomestatin
- 27.4°C 0.0°C
29
Heterocycle-Peptides
Schouten, J.A., et al. J. Am. Chem. Soc. 2003, 125, 5594-5595.Green, J.J., et al. J. Am. Chem. Soc. 2006, 128, 9809-9812.
- Peptides introduce versatility
- Additional interaction with G4 grooves/phosphate groups
30
Heterocycle-Peptides
>50:1 selectivity G4 DNA vs. duplex DNA
Schouten, J.A., et al. J. Am. Chem. Soc. 2003, 125, 5594-5595.Green, J.J., et al. J. Am. Chem. Soc. 2006, 128, 9809-9812.
31
Metal Complexes
- Ni(II) forces planarity, resulting in π stacking
- Piperidine interaction with phosphate backbone
Reed, J.E., et al. J. Am. Chem. Soc. 2006, 128, 5992-5993.
32
Metal Complexes
- Generation of aromatic motif
- >50:1 G4 DNA vs. duplex DNA
-
Reed, J.E., et al. J. Am. Chem. Soc. 2006, 128, 5992-5993.
ΔTm G4 ΔTm dsDNA
Ni(II) complex
32.8°C 0.0°C
telomestatin
27.4°C 0.0°C EC50 120 nM
33
Metal Complexes
34
G4 Ligand Issues
1. G4 structures can be polymorphic in vivo
Gabelica, V., et al. J. Am. Chem. Soc. 2007, 129, 895-904.
35
G4 Ligand Issues
2. Do G-quadruplex structures exist elsewhere in DNA ?
- Difficult to predict based on DNA sequence- A few have been found in promoter regions
of oncogenes – dual mechanism?
YES
Siddiqui-Jain, A., et al. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11593-11598.
36
Future Directions of G4 Ligands
Need deeper understanding of G4-ligandinteractions
Possible use as a gene suppressor ?
Metal complexes ?
37
Telomerase Inhibitors: Therapeutic Future
- Need more in vivo testing- Used in combination with traditional
therapy- What about other ~15% of cancer cells ?- Cure for cancer ?
“For every complex problem there is asolution that is simple, neat, and wrong”
- H.L. Mencken
38
AcknowledgementsProf. Helen E. Blackwell
Team Blackwell*Ben Gorske Blake Carlson *Beth Mascato*Grant Geske Aleeza Roth *Rick
McDonald*Jenny O’Neill Dr. Matt Bowman Prof. John
Berry*Qi Lin Wa Neng Thao*Sarah Fowler Margaret Wong*Daniel Fritz *Lingyin Li*Brent Bastian*Margie Mattmann*Christie McInnis*Reto Frei* Practice talk attendees
...I get by with a little helpfrom my friends
39
Supplemental Slides
40
Telomere Capping
- Dynamic equilibrium between G4 and non G4 state
- Telomere must be in linear form for telomerase activity
41
FRET Analysis (ref 26)
FRET analysisFluorescence Resonance
Energy Transfer
- Correlates temperature change with a stabilized/unstabilized DNA structure
42
TRAP Assay (ref 26)
Telomere Repeat Amplification Protocol
- Used for quantitative and qualitative telomerase inhibition
43
• www.txccc.org• www.childrenscancernetwork.org
44
DNA Replication
- Requires initial RNA primer
- Replication only proceeds in 5→3 direction
- After removal of terminal RNA primer, gap is left
- DNA cannot add to the 5' end (wrong direction)
http://www.senescence.info/telomeres.html
Primer removal
DNA base pairaddition
45
Telomere Capping
- Cell can replicate with a capped state, until telomere gets short, then it will uncap and telomerase will add length
- When a telomere is very short, it cannot be capped efficiently, and the single stranded G-rich DNA can form G-quadruplexes, thus making a target for G4 ligands
- Cancer cells with short telomeres must “expose” their loose end (become linear) to add on and keep living
46
G4 Ligand Issues
1. Selectivity G-quadruplex vs. duplex DNA
Minimize toxicity
vs.
47
G4 Ligand Char.
- π stacking ability of central core
- Positively charged substituents to interact with negatively charged phosphate backbone
Partial positive charge in center
Neidle, S., Lee, M.P.H., Parkinson, G. N. Nature. 2002, 417, 876-880.
48
Telomere Structure-Guanine (G)-Tetrad
- Higher order structure of single stranded, Guanine rich DNA
- Guanines are co-planar
- Occurs in telomeres when left “uncapped” by protective proteins
49
G4 Inhibitors -Proposed Mechanism
- Stabilization of G-quadruplex leads to telomerase inhibition
Mergny, J-L., et al. Nature Medicine. 1998, 4, 1366-1367.
50
Human Telomere
- Protects against gene deletion
- Usually capped by protective proteins
- When telomeres become critically short, they become uncapped and are vulnerable
51
Telomestatin Binding
Hurley, L.H., et al. J. Am. Chem. Soc. 2002, 124, 4844-4849.
- External binding
>70 fold selectivity G4 vs. duplex DNA